1,2-dipalmitoyl-3-phosphatidylethanolamine has been researched along with gemcitabine in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Arpicco, S; Beghelli, S; Costanzo, C; Dalla Pozza, E; Dando, I; Donadelli, M; Fattal, E; Lerda, C; Palmieri, M; Scarpa, A; Scupoli, MT; Zoratti, E | 1 |
1 other study(ies) available for 1,2-dipalmitoyl-3-phosphatidylethanolamine and gemcitabine
Article | Year |
---|---|
Targeting gemcitabine containing liposomes to CD44 expressing pancreatic adenocarcinoma cells causes an increase in the antitumoral activity.
Topics: 1,2-Dipalmitoylphosphatidylcholine; Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Cholesterol; Deoxycytidine; Flow Cytometry; Gemcitabine; Humans; Hyaluronan Receptors; Hyaluronic Acid; Liposomes; Mice; Mice, Nude; Microscopy, Confocal; Pancreatic Neoplasms; Phosphatidylethanolamines; Prodrugs; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |